- Home
- BMEA vs EEA Comparison
BMEA vs EEA Comparison
Compare BMEA & EEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- EEA
- Stock Information
- Founded
- BMEA 2017
- EEA 1986
- Country
- BMEA United States
- EEA Germany
- Employees
- BMEA N/A
- EEA N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- EEA Trusts Except Educational Religious and Charitable
- Sector
- BMEA Health Care
- EEA Finance
- Exchange
- BMEA Nasdaq
- EEA Nasdaq
- Market Cap
- BMEA 65.8M
- EEA 67.9M
- IPO Year
- BMEA 2021
- EEA N/A
- Fundamental
- Price
- BMEA $1.93
- EEA $10.28
- Analyst Decision
- BMEA Strong Buy
- EEA
- Analyst Count
- BMEA 10
- EEA 0
- Target Price
- BMEA $22.30
- EEA N/A
- AVG Volume (30 Days)
- BMEA 2.3M
- EEA 9.2K
- Earning Date
- BMEA 07-30-2025
- EEA 01-01-0001
- Dividend Yield
- BMEA N/A
- EEA 1.92%
- EPS Growth
- BMEA N/A
- EEA N/A
- EPS
- BMEA N/A
- EEA N/A
- Revenue
- BMEA N/A
- EEA N/A
- Revenue This Year
- BMEA N/A
- EEA N/A
- Revenue Next Year
- BMEA N/A
- EEA N/A
- P/E Ratio
- BMEA N/A
- EEA N/A
- Revenue Growth
- BMEA N/A
- EEA N/A
- 52 Week Low
- BMEA $1.29
- EEA $7.45
- 52 Week High
- BMEA $13.07
- EEA $9.26
- Technical
- Relative Strength Index (RSI)
- BMEA 50.04
- EEA 70.14
- Support Level
- BMEA $1.58
- EEA $9.85
- Resistance Level
- BMEA $2.03
- EEA $10.45
- Average True Range (ATR)
- BMEA 0.15
- EEA 0.12
- MACD
- BMEA -0.00
- EEA 0.02
- Stochastic Oscillator
- BMEA 80.00
- EEA 85.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.